Search Research
Search across 105,000+ research abstracts, articles, substances, health topics, keywords, and actions.
Found 778 results for "coronavirus disease"
Articles (216)
View all
Mar 24, 2020
A Fiasco in the Making? As the Coronavirus Pandemic Takes Hold, We Are Making Decisions Without Reliable Data
coronavirus disease, Covid-19, has been called a once-in-a-century pandemic . But it may also
JohnPAIoannidis
8 min
Jun 09, 2020
Op-Ed: To Citizens Wearing Medical Masks: You're Whacko Conspiracy Theorists
Coronavirus Disease": "Unless you are sick, a health care worker, or caring for someone who has COVID
jonrappoport
5 min
Jul 28, 2020
If COVID Fatalities Were 90.2% Lower, How Would You Feel About Schools Reopening?
By H. Ealy, M. McEvoy, M. Sava, S. Gupta, D. Chong, D. White, J. Nowicki
Children's Health Defense
35 min
Mar 31, 2020
Unprecedented Response to COVID-19 by Governments Prohibits Physical Contact and Cripples World Economy
Originally published on www.thevaccinereaction.org After officials at the World Health Organization (WHO) declared on Mar. 11, 2020 that outbreaks of a mutated coronavirus (COVID-19)1 2 had become a...
barbloe2
23 minAbstracts (562)
View allExosomes: Applications in respiratory infectious diseases and prospects for coronavirus disease 2019.
Exosomes are small extracellular vesicles of 30-150 nm diameter secreted by almost all cells. In recent years, with continuous deeper understanding of exosomes physiological functions, different reports have proven that exosomes can facilitate cell-to-cell communication by binding to target cells and transferring their contents, together with RNAs, DNAs, proteins, and lipids between cells and tissues. With advantages that exosomes can be involved in various types of physiological processes, such as blood coagulation, cellular homeostasis, inflammation, immune surveillance, stem cell differentiation, neuroprotection, and tissue regeneration and angiogenesis. Exosomes have been demonstrated that they can be applied in identification and treatment of multiple disorders such as cancers, cerebral ischemia, and respiratory infectious diseases. Importantly, researchers utilize application of exosomes in the treatment of various respiratory infectious diseases that have made some breakthrough progress. However, with the global pandemic of Coronavirus Disease 2019 (COVID-19), we have focused on applications of exosomes in respiratory infectious diseases and their serious complications, including influenza, TB, ARDS and sepsis. In this review, we explain the use of exosomes in various respiratory infectious diseases and their serious complications, and hope to provide new ideas for the treatment of new coronavirus infections.
Jia Feng, Ahmed Waqas, Zhihan Zhu, Lukui Chen, J Biomed Nanotechnol
Review
The spike effect of acute respiratory syndrome coronavirus 2 and coronavirus disease 2019 vaccines on blood pressure.
Among the various comorbidities potentially worsening the clinical outcome in patients hospitalized for the acute respiratory syndrome coronavirus-2 (SARS-CoV-2), hypertension is one of the most prevalent. However, the basic mechanisms underlying the development of severe forms of coronavirus disease 2019 (COVID-19) among hypertensive patients remain undefined and the direct association of hypertension with outcome in COVID-19 is still a field of debate. Experimental and clinical data suggest that SARS-CoV-2 infection promotes a rise in blood pressure (BP) during the acute phase of infection. Acute increase in BP and high in-hospital BP variability may be tied with acute organ damage and a worse outcome in patients hospitalized for COVID-19. In this context, the failure of the counter-regulatory renin-angiotensin-system (RAS) axis is a potentially relevant mechanism involved in the raise in BP. It is well recognized that the efficient binding of the Spike (S) protein to angiotensin converting enzyme 2 (ACE2) receptors mediates the virus entry into cells. Internalization of ACE2, downregulation and malfunction predominantly due to viral occupation, dysregulates the protective RAS axis with increased generation and activity of angiotensin (Ang) II and reduced formation of Ang. Thus, the imbalance between Ang II and Angcan directly contribute to excessively rise BP in the acute phase of SARS-CoV-2 infection. A similar mechanism has been postulated to explain the raise in BP following COVID-19 vaccination ("Spike Effect" similar to that observed during the infection of SARS-CoV-2). S proteins produced upon vaccination have the native-like mimicry of SARS-CoV-2 S protein's receptor binding functionality and prefusion structure and free-floating S proteins released by the destroyed cells previously targeted by vaccines may interact with ACE2 of other cells, thereby promoting ACE2 internalization and degradation, and loss of ACE2 activities.
Fabio Angeli, Martina Zappa, Gianpaolo Reboldi, Giorgio Gentile, Monica Trapasso, Antonio Spanevello, Paolo Verdecchia, Eur J Intern Med
Human Study
High-dose vitamin C may reduce the mortality and improve oxygen support status in patients with Coronavirus disease 2019 without adverse events.
BACKGROUND: The inflammatory reaction is the main cause of acute respiratory distress syndrome and multiple organ failure in patients with Coronavirus disease 2019, especially those with severe and critical illness. Several studies suggested that high-dose vitamin C reduced inflammatory reaction associated with sepsis and acute respiratory distress syndrome. This study aimed to determine the efficacy and safety of high-dose vitamin C in Coronavirus disease 2019. METHODS: We included 76 patients with Coronavirus disease 2019, classified into the high-dose vitamin C group (loading dose of 6g intravenous infusion per 12 hr on the first day, and 6g once for the following 4 days, n=46) and the standard therapy group (standard therapy alone, n=30). RESULTS: The risk of 28-day mortality was reduced for the high-dose vitamin C versus the standard therapy group (HR=0.14, 95% CI, 0.03-0.72). Oxygen support status was improved more with high-dose vitamin C than standard therapy (63.9% vs 36.1%). No safety events were associated with high-dose vitamin C therapy. CONCLUSION: High-dose vitamin C may reduce the mortality and improve oxygen support status in patients with Coronavirus disease 2019 without adverse events.
Dengfeng Gao, Min Xu, Gang Wang, Jianrui Lv, Xiaorong Ma, Yonghong Guo, Dexin Zhang, Huiyun Yang, Wei Jiang, Fuxue Deng, Guozhi Xia, Ziwei Lu, Lv Lv, Shouping Gong, Aging (Albany NY)
Human Study
Nigella sativa L as a potential phytotherapy for coronavirus disease 2019.
Background: Coronaviruses are responsible for several human diseases, such as the infectious novel coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).is a natural food supplement with a known safety profile that may provide a wealth of documented antiviral compounds. Objective: To explore the studies supporting thepotential for hitting SARS-CoV-2 targets. Methods: A literature search for published or preprint in silico studies between 1990 and 2020 in electronic databases (PubMed, Science Direct, Scopus, and Google Scholar) was performed for the terms Nigella sativa,, and. Results: At least 8 in silico studies have shown that some compounds of, including nigelledine,α-hederin, hederagenin, thymohydroquinone, and thymoquinone, had high to moderate affinity with SARS-CoV-2 enzymes and proteins. These compounds may potentially inhibit SARS-CoV-2 replication and. Conclusions: These preliminary data of in silico studies proposeas a potential phytotherapy candidate for COVID-19. Further preclinical experimental evidence is required followed by a Phase I clinical trial. (. 2020; 81:XXX-XXX).
Dr Abdulrahman E Koshak, Prof Emad A Koshak, Curr Ther Res Clin Exp
Review
Cervical lymphadenopathy following coronavirus disease 2019 vaccine.
OBJECTIVE: Patients with coronavirus disease vaccine associated lymphadenopathy are increasingly being referred to healthcare services. This work is the first to report on the incidence, clinical course and imaging features of coronavirus disease vaccine associated cervical lymphadenopathy, with special emphasis on the implications for head and neck cancer services. METHODS: This was a retrospective cohort study of all patients referred to our head and neck cancer clinics between 16 December 2020 and 12 March 2021. The main outcomes measured were the proportion of patients with vaccine-associated cervical lymphadenopathy, and the clinical and imaging characteristics. RESULTS: The incidence of vaccine-associated cervical lymphadenopathy referrals was 14.8 per cent (n = 13). Five patients (38.5 per cent) had abnormal-looking enlarged and rounded nodes with increased vascularity. Only seven patients (53.9 per cent) reported full resolution within an average of 3.1± 2.3 weeks. CONCLUSION: Coronavirus disease vaccine associated cervical lymphadenopathy can mimic malignant lymphadenopathy and therefore might prove challenging to diagnose and manage correctly. Healthcare services may encounter a significant increase in referrals.
A K Abou-Foul, E Ross, M Abou-Foul, A P George, J Laryngol Otol
Human Study
